COMPARISON WITH 

EXISTING TECHNOLOGY

ALZHEIMER 

Although the start is late, clinical progress will be completed faster than the three companies below due to clinical data in China and Japan.

It is also planning to enter the market within 3 years instead of the existing 5 years.

@ EXISTING A Product

SOURCE & CONTENT: Cord Blood Mesenchymal Stem Cells
PROS & CONS: A product and placebo through Ommaya reservoir 3 doses of each ventricle at 4-week intervals 

CLINICAL STAGE: Phase 1/2a 

@ EXISTING B Product

SOURCE & CONTENT: Functional cells extracted from placenta tissue
PROS & CONS: Unable to validate
CLINICAL STAGE:  Phase 1/2a 


@ EXISTING C Product

SOURCE & CONTENT: autologous adipose stem cells  
PROS & CONS: Fat stem cells are restricted from passing through BBB, the gateway to the brain
CLINICAL STAGE:  Phase 1/2a completed  


@ OUR R&D

SOURCE & CONTENT: CORD BLOOD -> STEM CELLS -> EXOSOMES
PROS & CONS: Our specialized exosomes are 30mm to 150mm in size and are effective in preventing and treating Alzheimer's disease by passing BBB rules
CLINICAL STAGE: Full clinical trial scheduled in 2023

NOVAMED INTL

ⓒ Since 2015

SERVICE

Tel: +82-70-8830-2008

E-mail: novamed00@gmail.com

Whatsapp: +82-10-8603-7697
Mon - Fri AM 10:00 - 16:00
Sat.Sun.National holiday Off

#B107, Hillstate Ecomoonjeong BLDG, Bupwon-ro 4gil 10, Seoul, Korea  ㅣ  Biz License 898-14-00118  ㅣ  Communication Sales Business Report 0000-SEOUL-0000

Hosting by I'MWEB